For instance, monoclonal antibodies against different regions of IL-2 have been developed to selectively target the binding of IL-2 with different receptor subunits.16–18 PEGylation is another potential strategy for selectively modulating the effects of IL-2,19,20 and PEGylated IL-2 variants that preferentially bind to trimeric or dimeric IL-2R to skew immune homeostasis in favour of Tregs versus Teff cells are being explored in the treatment of autoimmune disease and cancer. This evidence concerns the gene IL2 and cancer.